Ramón García-Gómez
Hospital General Universitario Gregorio Marañón · 23 works · 5,835 citations · h-index 8
Top works
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial
- Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study
- Preoperative High-Dose Cisplatin Versus Moderate- Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial
- Phase II study of mitonafide in non-small cell lung cancer (NSCLC)
- Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer
- Effect of the Methylenetetrahydrofolate Reductase C677T Polymorphism on Patients with Cisplatin/Gemcitabine–Treated Stage IV Non–Small-Cell Lung Cancer
- Valor pronóstico de la expresión y amplificación genética de c-erbB-2 en el carcinoma microcítico de pulmón
- Prognostic Value of ERBB2 Amplification and Protein Expression in Small Cell Lung Cancer
- Cisplatin (CDDP) plus vinorelbine (NVB) as first-line treatment for advanced non-small-cell lung cancer (NSCLC): Retrospective analysis to improve the patient’s convenience on day 8 NVB administration
- Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03)
- Randomized phase II trial (RENO): Efficacy results of oral vinorelbine or etoposide combined with cisplatin in chemo-radiotherapy treatment of locally advanced NSCLC (LA-NSCLC)—SLCG 10/02.
- Vinorelbine, ifosfamide and cisplatin regimen in inoperable non small cell lung cancer patients
- P2-286: Clinical experience with single agent oral vinorelbine in first-line advanced non-small-cell lung cancer (NSCLC) treatment of elderly patients (p)
- Randomized phase II trial of oral vinorelbine (OV) and cisplatin (P) followed by maintenance with single-agent OV versus (vs) gemcitabine (GEM) and P followed by maintenance with single-agent GEM as first-line chemotherapy (CT) in locally advanced (LA) or metastatic non-small-cell lung cancer (NSCLC) patients (pts) with squamous (sq) histological type.
- Prospective study into the necessity of hemogram on day 8 in oral vinorelbine and cisplatin regimen.
- P2-284: First-line treatment with vinorelbine (VRL) plus gemcitabine (GEM) for elderly patients with advanced non-small-cell lung cancer (NSCLC): Molecular correlates
- Clinical profile and patterns of progression (PD) of patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line bevacizumab (B): AVVA study.
- Cisplatin (CDDP) plus oral vinorelbine (NVBO) as first-line treatment for advanced non-small cell lung cancer (NSCLC): Prospective analysis to improve the patient’s convenience on day 8 NVBO administration.